Johnson & Johnson $JNJ Shares Sold by DDD Partners LLC

DDD Partners LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 10.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 130,441 shares of the company’s stock after selling 14,833 shares during the period. Johnson & Johnson comprises approximately 2.1% of DDD Partners LLC’s investment portfolio, making the stock its 19th biggest position. DDD Partners LLC’s holdings in Johnson & Johnson were worth $19,925,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. Apexium Financial LP grew its stake in Johnson & Johnson by 10.7% during the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock valued at $3,978,000 after acquiring an additional 2,310 shares in the last quarter. Avanza Fonder AB grew its stake in Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock valued at $35,842,000 after acquiring an additional 6,566 shares in the last quarter. Joel Isaacson & Co. LLC grew its stake in Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock valued at $12,294,000 after acquiring an additional 2,526 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. grew its stake in Johnson & Johnson by 7.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock valued at $12,164,000 after acquiring an additional 4,816 shares in the last quarter. Finally, Klingman & Associates LLC grew its stake in Johnson & Johnson by 13.4% during the 1st quarter. Klingman & Associates LLC now owns 16,984 shares of the company’s stock valued at $2,817,000 after acquiring an additional 2,005 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $190.38 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.07. The stock has a market capitalization of $458.69 billion, a P/E ratio of 18.38, a PEG ratio of 2.26 and a beta of 0.40. The company has a 50 day moving average price of $182.26 and a 200 day moving average price of $166.13. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Analyst Ratings Changes

Several brokerages recently issued reports on JNJ. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Loop Capital set a $190.00 price target on shares of Johnson & Johnson in a research note on Wednesday. Barclays increased their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Finally, HSBC increased their price target on shares of Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $199.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.